How long should we maintain long-term azithromycin treatment in cystic fibrosis patients?

Pediatric Pulmonology

Volumn 50, Issue 1, 2015, Pages 103-104

  Willekens, Julie ^a   Eyns, Hanneke ^a   Malfroot, Anne ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL COLONIZATION; CYSTIC FIBROSIS; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; LONG TERM CARE; LUNG FUNCTION; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT DURATION; FEMALE; MALE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE;

EID: 84922709271     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22981     Document Type: Letter

References (6)

1. Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, and the AZ0004 Macrolide Study Team. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012;47:641-648.
2. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-216.
3. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984.
4. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ. Campbell PW III, for the Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290: 1749-1756.
5. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis - long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26: 8-12.
6. Nick JA, Chmiel J, Forssen A, Hamblett NM, Moskowitz SM, Saiman L, Nichols D. Azithromycin appears to inhibit inhaled tobramycin but not aztreonam when targeting P. aeruginosa in the CF airway. Pediatr Pulmonol (27th Annual North American Cystic Fibrosis Conference) 2013; p 305; abstract 277.